Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Odevixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved FDF
Sponsor : Albireo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bylvay (Odevixibat) is theI BAT inhibitor and first drug approved in the U.S. for the treatment of pruritus in patients 3 months of age and older in all types of progressive familial intrahepatic cholestasis (PFIC).
Product Name : Bylvay
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 20, 2023
Lead Product(s) : Odevixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Sponsor : Albireo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Odevixibat
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Albireo Pharma
Deal Size : $135.0 million
Deal Type : Licensing Agreement
Details : This agreement exemplifies Albireo’s commitment to providing global availability of Bylvay, particularly in areas like Japan where high prevalence translates to a sizable number of patients who currently have no approved treatment option.
Product Name : Bylvay
Product Type : Miscellaneous
Upfront Cash : $15.0 million
October 12, 2021
Lead Product(s) : Odevixibat
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Albireo Pharma
Deal Size : $135.0 million
Deal Type : Licensing Agreement
Reset All
